PPARG and Hypercholesterolemia: Similarly, Subramanian [69] et al. demonstrated that PPARγ ligands, thiazolidinedione compounds, inhibit angiotensin II (Ang II)-induced atherosclerosis by interacting with VSMCs-specific PPARγ in hypercholesterolemia mice.